Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we performed single-cell RNA-seq, BCR-seq,...
S. Baaklini, A. Sarrabay, C. Barthelemy et al.· Blood· 0 citations
Resistance to therapeutic interventions contributes to poor long-term cancer patient outcomes. Adaptation to therapy, a common mechanism of drug resistance involving drug-induced activation of pro-survival oncogenic processes, poses a challenge for the implementation of effective precision therapies. Here, we addressed...
Augustin Luna, He-Ping Wang, Lin Wang et al.· Cancer Research· 0 citations
Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...
Xu-Bin Li, Christopher R. Flowers, Michael R. Green· Blood Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.